Inspire Medical Systems, Inc. (FRA:2DR)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.84B -11.7% |
| Revenue (ttm) | 786.67M +4.3% |
| Net Income | 118.20M +154.2% |
| EPS | 4.11 +164.4% |
| Shares Out | n/a |
| PE Ratio | 15.10 |
| Forward PE | 51.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40 |
| Open | 64.00 |
| Previous Close | 61.00 |
| Day's Range | 62.00 - 64.00 |
| 52-Week Range | 33.60 - 121.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open ai... [Read more]
Financial Performance
In 2025, Inspire Medical Systems's revenue was $911.98 million, an increase of 13.60% compared to the previous year's $802.80 million. Earnings were $145.42 million, an increase of 171.77%.
Financial numbers in USD Financial StatementsNews
Inspire Medical price target raised to $78 from $62 at Truist
Truist raised the firm’s price target on Inspire Medical (INSP) to $78 from $62 and keeps a Hold rating on the shares as part of a broader research note previewing…
Inspire Medical price target raised to $75 from $65 at Mizuho
Mizuho raised the firm’s price target on Inspire Medical (INSP) to $75 from $65 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical devices…
Inspire Medical initiated with an Underweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Inspire Medical (INSP) with an Underweight rating and $65 price target The firm rolled out coverage of the medical suppliers and devices gro...
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026
MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, Nove...
Inspire Medical announces approval of new CPT codes by AMA panel
Inspire Medical (INSP) Systems announced that the American Medical Association CPT Editorial Panel has approved the establishment of a new set of Current Procedural Terminology codes that accurately d...
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minima...
Inspire Medical price target raised to $75 from $60 at RBC Capital
RBC Capital raised the firm’s price target on Inspire Medical (INSP) to $75 from $60 and keeps a Sector Perform rating on the shares as part of a broader research…
Inspire Medical price target raised to $97 from $71 at Freedom Broker
Freedom Broker raised the firm’s price target on Inspire Medical (INSP) to $97 from $71 and keeps a Buy rating on the shares. The AMA CPT Editorial Panel Meeting on…
Inspire Medical price target raised to $80 from $75 at Stifel
Stifel analyst Jonathan Block raised the firm’s price target on Inspire Medical (INSP) to $80 from $75 and keeps a Buy rating on the shares. The stock has responded to…
Inspire Medical Systems Transcript: Wells Fargo 21st Annual Healthcare Conference
Inspire V's closed-loop technology and new coding clarity are driving improved outcomes and operational efficiency, with sequential revenue growth expected in the second half of the year. Project Horizon reallocates $30 million to growth, while Inspire VI and digital initiatives aim to boost future adherence and access.
Inspire Medical Systems Slides: Wells Fargo 21st Annual Healthcare Conference
Inspire Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minima...
Inspire Medical price target raised to $60 from $54 at JPMorgan
JPMorgan raised the firm’s price target on Inspire Medical (INSP) to $60 from $54 and keeps a Neutral rating on the shares.
Inspire Medical price target raised to $65 from $55 at Mizuho
Mizuho raised the firm’s price target on Inspire Medical (INSP) to $65 from $55 and keeps an Outperform rating on the shares.
Inspire Medical price target raised to $54 from $40 at Evercore ISI
Evercore ISI raised the firm’s price target on Inspire Medical (INSP) to $54 from $40 and keeps an In Line rating on the shares.
Inspire Medical price target raised to $45 from $39 at BofA
BofA analyst Travis Steed raised the firm’s price target on Inspire Medical (INSP) to $45 from $39 and keeps an Underperform rating on the shares. The firm, which updated its…
Inspire Medical price target raised to $62 from $54 at Truist
Truist raised the firm’s price target on Inspire Medical (INSP) to $62 from $54 and keeps a Hold rating on the shares. Inspire Medical delivered a better-than-feared quarter with a…
Inspire Medical price target raised to $75 from $65 at Stifel
Stifel raised the firm’s price target on Inspire Medical (INSP) to $75 from $65 and keeps a Buy rating on the shares.
Oppenheimer tactically upgrades Inspire Medical despite noisy fundamentals
As previously reported, Oppenheimer analyst Suraj Kalia upgraded Inspire Medical (INSP) to Outperform from Perform with an $85 price target The firm notes the company’s Q2 revenues of $201M slightly…
Inspire Medical upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Inspire Medical (INSP) to Outperform from Perform with an $85 price target
Inspire Medical price target raised to $60 from $55 at Piper Sandler
Piper Sandler raised the firm’s price target on Inspire Medical (INSP) to $60 from $55 and keeps a Neutral rating on the shares following quarterly results. The firm notes management…
Inspire Medical Systems Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue decline 7.6% to $200.6M due to coding and reimbursement disruptions, but profitability and cash flow exceeded expectations. Project Horizon was launched to drive future growth, and the 2026 outlook was raised, with sequential improvement expected in the second half.
Inspire Medical Systems Earnings release: Q2 2026
Inspire Medical Systems released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Inspire Medical Systems Quarterly report: Q2 2026
Inspire Medical Systems has published its Q2 2026 quarterly earnings report on August 3, 2026.
Inspire Medical Systems Slides: Q2 2026
Inspire Medical Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.